MA54741A - Composés thiényl-aniline destinés au traitement d'affections de la peau - Google Patents
Composés thiényl-aniline destinés au traitement d'affections de la peauInfo
- Publication number
- MA54741A MA54741A MA054741A MA54741A MA54741A MA 54741 A MA54741 A MA 54741A MA 054741 A MA054741 A MA 054741A MA 54741 A MA54741 A MA 54741A MA 54741 A MA54741 A MA 54741A
- Authority
- MA
- Morocco
- Prior art keywords
- thienyl
- treatment
- skin conditions
- aniline compounds
- aniline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769832P | 2018-11-20 | 2018-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54741A true MA54741A (fr) | 2021-11-24 |
Family
ID=70773567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054741A MA54741A (fr) | 2018-11-20 | 2019-11-20 | Composés thiényl-aniline destinés au traitement d'affections de la peau |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12466818B2 (fr) |
| EP (1) | EP3911313A4 (fr) |
| JP (1) | JP7546297B2 (fr) |
| CN (2) | CN113498340A (fr) |
| AU (1) | AU2019384645B2 (fr) |
| CA (1) | CA3120352A1 (fr) |
| MA (1) | MA54741A (fr) |
| WO (1) | WO2020106305A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| JP7546297B2 (ja) | 2018-11-20 | 2024-09-06 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのチエニル－アニリン化合物 |
| CA3120351A1 (fr) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau |
| US12378240B2 (en) | 2018-11-20 | 2025-08-05 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| US11010862B1 (en) * | 2019-11-14 | 2021-05-18 | Advanced Micro Devices, Inc. | Reduced bandwidth tessellation factors |
| IL312977A (en) | 2021-11-23 | 2024-07-01 | Nflection Therapeutics Inc | Formulations of pyrrolopyridine-aniline compounds |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271164A (en) | 1979-04-16 | 1981-06-02 | Warner-Lambert Company | 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives |
| GB9420168D0 (en) | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
| AU757046B2 (en) | 1997-07-01 | 2003-01-30 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| JP2002509536A (ja) | 1997-07-01 | 2002-03-26 | ワーナー−ランバート・カンパニー | ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用 |
| JP2910748B2 (ja) | 1997-11-12 | 1999-06-23 | 日本電気株式会社 | 異質同軸部材の端面の球状加工装置及びその方法 |
| GEP20032999B (en) | 1999-01-13 | 2003-06-25 | Warner Lambert Co | 1-Heterocycle Substituted Diarylamines |
| TWI343377B (en) | 2002-03-13 | 2011-06-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| AU2003225161A1 (en) | 2002-04-24 | 2003-11-10 | Koo, Han-Mo | Enhancement of human epidermal melanogenesis |
| CA2492112A1 (fr) | 2002-08-06 | 2004-02-19 | F. Hoffmann-La Roche Ag | 6-alcoxy-pyrido-pyrimidines utilisees comme inhibiteurs de la map kinase p-38 |
| NZ547481A (en) | 2003-11-19 | 2009-12-24 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
| JP2008503446A (ja) * | 2004-05-06 | 2008-02-07 | プレキシコン，インコーポレーテッド | Ｐｄｅ４ｂ阻害剤及びその使用 |
| PT2298768E (pt) | 2004-06-11 | 2012-12-05 | Japan Tobacco Inc | Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro |
| US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| AR051248A1 (es) | 2004-10-20 | 2007-01-03 | Applied Research Systems | Derivados de 3-arilamino piridina |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| CN103524392B (zh) | 2005-10-07 | 2018-06-01 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶 |
| GB0601962D0 (en) * | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| WO2007123939A2 (fr) | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Nouveaux arylamino n-hétéraryles en tant qu'inhibiteurs de mek |
| GB0616214D0 (en) | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| CA2658725A1 (fr) * | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Procedes d'utilisation de modulateurs pi3k etmek |
| EP2069359B1 (fr) | 2006-08-21 | 2014-11-12 | Genentech, Inc. | Composés aza-benzothiophényle et leurs procédés d'utilisation |
| WO2008024725A1 (fr) | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Composés aza-benzofuranyle et leurs procédés d'utilisation |
| JP5432716B2 (ja) | 2006-10-17 | 2014-03-05 | ヌーボ リサーチ インコーポレイテッド | ジクロフェナクゲル |
| EP2113500A1 (fr) | 2006-10-31 | 2009-11-04 | Takeda Pharmaceutical Company Limited | Inhibitêur du kinàse MAPK/ERK |
| CA2672327A1 (fr) | 2006-11-30 | 2008-06-05 | Genentech, Inc. | Composes azaindolyliques et procedes d'utilisation de ceux-ci |
| CL2008001373A1 (es) | 2007-05-11 | 2008-11-21 | Bayer Schering Pharma Ag | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. |
| WO2008148034A1 (fr) * | 2007-05-25 | 2008-12-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de mapk/erk kinase |
| GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| ES2387707T3 (es) | 2007-12-21 | 2012-09-28 | Genentech, Inc. | Azaindolizinas y procedimientos de uso |
| GB0801081D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| GB0801080D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| EP2240494B1 (fr) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Dérivés de thiénopyridine utilisés comme inhibiteurs de mek |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| DE102010012594A1 (de) | 2010-03-23 | 2011-09-29 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten |
| US9422262B2 (en) | 2010-09-24 | 2016-08-23 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
| NZ608592A (en) | 2010-11-05 | 2015-08-28 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| WO2012099968A1 (fr) | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions et procédés de traitement de maladies associées à un cancer de la peau |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| WO2012171484A1 (fr) | 2011-06-17 | 2012-12-20 | 中国中化股份有限公司 | Composés de cyanoaniline substitués, leur préparation et leur utilisation |
| WO2014179785A1 (fr) | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Répulsifs améliorés contre les abeilles domestiques et leurs utilisations |
| US10835513B2 (en) | 2013-06-28 | 2020-11-17 | The Regents Of The University Of California | Methods and treatments for the learning and memory deficits associated with Noonan syndrome |
| US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| CN105384754B (zh) | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| JP2018535238A (ja) | 2015-11-30 | 2018-11-29 | イグナイタ インコーポレイテッド | 局所製剤 |
| EP3301094A1 (fr) | 2016-09-30 | 2018-04-04 | Mutabilis | Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes |
| CA3063535A1 (fr) | 2017-05-19 | 2018-11-22 | Nflection Therapeutics, Inc. | Composes heteroaromatiques-aniline fusionnes pour le traitement de troubles dermiques |
| MA49141A (fr) | 2017-05-19 | 2020-03-25 | Nflection Therapeutics Inc | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau |
| US11395823B2 (en) | 2018-01-09 | 2022-07-26 | Duke University | Topical administration of MEK inhibiting agents for the treatment of skin disorders |
| WO2020101878A2 (fr) | 2018-10-29 | 2020-05-22 | The Johns Hopkins University | Traitement de rasopathie |
| WO2020106304A1 (fr) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Formulations topiques |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| US12378240B2 (en) | 2018-11-20 | 2025-08-05 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| JP7546297B2 (ja) | 2018-11-20 | 2024-09-06 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのチエニル－アニリン化合物 |
| EP4233834A3 (fr) | 2018-11-20 | 2023-10-25 | NFlection Therapeutics, Inc. | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance |
| CA3120351A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau |
| IL301496A (en) | 2020-09-24 | 2023-05-01 | Nflection Therapeutics Inc | Treatment of cognitive dysfunction with pyrrolopyridine-aniline compounds |
| EP4281055A4 (fr) | 2021-01-21 | 2025-06-18 | NFlection Therapeutics, Inc. | Formes cristallines d'un composé de pyrrolopyridine-aniline |
| JP2024503893A (ja) | 2021-01-21 | 2024-01-29 | エヌフレクション セラピューティクス インコーポレイテッド | ピロロピリジン－アニリン化合物を調製するための方法 |
-
2019
- 2019-11-20 JP JP2021527910A patent/JP7546297B2/ja active Active
- 2019-11-20 US US17/294,779 patent/US12466818B2/en active Active
- 2019-11-20 WO PCT/US2019/000067 patent/WO2020106305A1/fr not_active Ceased
- 2019-11-20 AU AU2019384645A patent/AU2019384645B2/en active Active
- 2019-11-20 CA CA3120352A patent/CA3120352A1/fr active Pending
- 2019-11-20 CN CN201980089585.XA patent/CN113498340A/zh active Pending
- 2019-11-20 EP EP19887349.9A patent/EP3911313A4/fr active Pending
- 2019-11-20 CN CN202311548396.9A patent/CN117551073A/zh active Pending
- 2019-11-20 MA MA054741A patent/MA54741A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117551073A (zh) | 2024-02-13 |
| AU2019384645A1 (en) | 2021-06-10 |
| US12466818B2 (en) | 2025-11-11 |
| EP3911313A4 (fr) | 2022-10-12 |
| AU2019384645B2 (en) | 2025-08-21 |
| CN113498340A (zh) | 2021-10-12 |
| EP3911313A1 (fr) | 2021-11-24 |
| CA3120352A1 (fr) | 2020-05-28 |
| US20220204486A1 (en) | 2022-06-30 |
| JP2022510586A (ja) | 2022-01-27 |
| WO2020106305A1 (fr) | 2020-05-28 |
| JP7546297B2 (ja) | 2024-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| EP3911313A4 (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
| EP3448389A4 (fr) | Composés de quinazoline et d'indole destinés au traitement de troubles médicaux | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| EP3883567A4 (fr) | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau | |
| EP3784260A4 (fr) | Compositions pour le traitement d'affections cutanées | |
| MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| EP3950686A4 (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| PL3405215T3 (pl) | Sposoby leczenia choroby danona i innych zaburzeń autofagii | |
| MA53664A (fr) | Composés destinés au traitement de certaines leucémies | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3790563A4 (fr) | Compositions permettant le traitement d'affections cutanées | |
| EP3664812A4 (fr) | Compositions topiques pour la peau destinées au traitement de l'érythème ou de l'inflammation cutanée | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP3672587A4 (fr) | Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques | |
| EP3959213C0 (fr) | Inhibiteurs de jak à base de pyrimidine pour le traitement de maladies de la peau | |
| EP3773632A4 (fr) | Méthodes de traitement de glioblastomes exprimant l'egfrviii | |
| EP3593803A4 (fr) | Composés destinés au traitement de maladies causées par l'accumulation d'oxalate | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3927428A4 (fr) | Méthodes de traitement d'affections respiratoires |